[Breaking] Moderna Stock Soars 126%... Personalized mRNA Cancer Treatment Succeeds in Phase 3 Melanoma Trial
Moderna (NASDAQ: MRNA) is drawing market attention with a sharp surge in early trading. As of 11:13 p.m. on the 19th, Korean time, Moderna was trading at $142.48, up $79.52, or 126.30%, from the previous close. The surge follows positive results from a Phase 3 trial of a personalized mRNA-based ca
![[Breaking] Moderna Stock Soars 126%... Personalized mRNA Cancer Treatment Succeeds in Phase 3 Melanoma Trial](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F08%2F599429%2F636767cd6cef84db%2Foriginal.webp&w=1920&q=75)
Moderna (NASDAQ: MRNA) is drawing market attention with a sharp surge in early trading.
As of 11:13 p.m. on the 19th, Korean time, Moderna was trading at $142.48, up $79.52, or 126.30%, from the previous close.
The surge follows positive results from a Phase 3 trial of a personalized mRNA-based cancer therapy being co-developed with Merck (NYSE: MRK). Market interest is focused on the fact that this is the first time a personalized neoantigen therapy and an mRNA-based cancer treatment have achieved positive Phase 3 results. Attention is now on how this achievement will affect the market's evaluation of Moderna's mRNA technology and the company's future stock performance.
Phase 3 Melanoma Trial Meets Both RFS and DMFS Endpoints
Merck, known as MSD outside the United States and Canada, and Moderna announced positive topline results from the Phase 3 'INTerpath-001' trial, which evaluated a combination regimen of the individualized neoantigen therapy (INT) 'intismeran autogene' (V940 or mRNA-4157) and Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) as adjuvant treatment.
The trial enrolled patients with fully resected Stage IIB–IV melanoma. The results met the primary endpoint of recurrence-free survival (RFS) as well as the key secondary endpoint of distant metastasis-free survival (DMFS).
According to the companies, this is the first positive Phase 3 result for both an individualized neoantigen therapy and an mRNA-based cancer treatment. It is also the first Phase 3 trial to demonstrate a clinically meaningful improvement over KEYTRUDA monotherapy, the standard immuno-oncology agent, in adjuvant therapy for patients with resected melanoma.
A pre-planned interim analysis showed that the intismeran plus KEYTRUDA combination statistically significantly and clinically meaningfully improved both recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone. The trial enrolled patients with fully resected Stage IIB, IIC, III, or IV cutaneous melanoma who had not previously received systemic therapy.
The trial will continue as planned, and other key secondary endpoints, including overall survival (OS), will be analyzed.
'No New Safety Signals'... Data to Be Presented at Medical Conference
No new safety signals were observed. The safety profile of the intismeran and KEYTRUDA combination in this trial was consistent with previously reported findings from combination studies. Merck and Moderna plan to present detailed data at an upcoming international medical conference and submit the results to regulatory authorities.
Experts Call It a Turning Point in Cancer Treatment
Trial investigator Georgina Long, Medical Director at Melanoma Institute Australia and head of the Melanoma Oncology and Translational Research division at the University of Sydney, described the results as a significant turning point in melanoma adjuvant therapy. Noting that intismeran is designed based on the unique mutational 'fingerprint' of each patient's tumor, she said the Phase 3 trial was the first to show that, in combination with KEYTRUDA, it can reduce the risk of recurrence or death compared with KEYTRUDA monotherapy in patients with fully resected Stage IIB–IV melanoma. Professor Long said the combination has the potential to establish a new paradigm in post-surgical adjuvant therapy for melanoma, helping patients remain cancer-free for longer.
Dean Y. Li, President of Merck Research Laboratories, explained that the goal of adjuvant therapy, which intervenes at an earlier stage of disease when the potential for cure is relatively high, is to increase the chance of curing more patients after surgery. He said the first Phase 3 results of the intismeran and KEYTRUDA combination support the potential of more personalized cancer treatment strategies, emphasizing that the individualized neoantigen therapy has the potential to redefine how fully resected Stage IIB–IV melanoma is treated.
Moderna CEO Stéphane Bancel called the Phase 3 results a major milestone in cancer research. He said that the concept of creating an individual mRNA therapy targeting one patient's cancer has long been close to an aspiration, but it is now becoming a reality. He added that, together with Merck, the technology has begun to show its potential to address a significant unmet medical need in melanoma adjuvant therapy.
'INTerpath' Program Encompasses Nine Trials in Total
Merck and Moderna are currently conducting the 'INTerpath' clinical development program, which evaluates intismeran in combination with anticancer agents including KEYTRUDA or as monotherapy. The INTerpath program includes a total of nine Phase 2 and Phase 3 trials across multiple cancer types and stages, including melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and renal cell carcinoma.
In addition, the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating post-surgical adjuvant therapy in melanoma, as well as a Phase 1 trial examining post-surgical adjuvant therapy in pancreatic ductal adenocarcinoma and perioperative treatment potential in gastric cancer and NSCLC, are also underway.
Phase 2b Trial Showed 49% Reduction in Recurrence or Death Risk
The Phase 3 results build on earlier success in the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial. According to five-year follow-up data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the intismeran and KEYTRUDA combination reduced the risk of recurrence or death by 49% compared with KEYTRUDA monotherapy, with a hazard ratio (HR) of 0.51 and a 95% confidence interval of 0.294–0.887. The risk of distant metastasis or death was reduced by 59%, with a hazard ratio of 0.411 and a 95% confidence interval of 0.200–0.843.
The Phase 3 results have once again highlighted the potential of mRNA-based cancer treatment strategies individually manufactured to match the mutational characteristics of each patient's tumor. Attention is now focused on how the detailed clinical data to be released, overall survival results, and regulatory decisions will affect not only the commercialization prospects of intismeran but also Moderna's mRNA cancer therapy pipeline and corporate value.
['Seohak! Star' is overseas stock content, including U.S. stocks, provided by CBC News. We will strive to continue offering readers a wide range of information. All investments are made at each individual's own judgment and discretion, and the final responsibility lies with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



